Why Pitney Bowes Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
Portfolio Pulse from Avi Kapoor
Pitney Bowes shares surged over 12% in pre-market trading after selling part of its e-commerce business to Stord. Other notable pre-market movers include Cognition Therapeutics, Longeveron, and Abbott Laboratories, among others.
July 29, 2024 | 9:26 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Abbott Laboratories shares fell 6.6% after a jury ordered the company to pay $495 million in a baby-formula verdict.
The significant financial penalty from the baby-formula verdict is likely to negatively impact Abbott's financials and investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Cognition Therapeutics shares gained 46% after announcing an investor presentation to discuss results from its phase 2 SHINE study.
Positive anticipation around the phase 2 SHINE study results is driving the stock price up.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Longeveron shares climbed 36.3% after disclosing study results from the CLEAR MIND Phase 2a clinical trial.
Positive clinical trial results for Lomecel-B in mild Alzheimer’s disease are boosting investor confidence.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Pitney Bowes shares rose 12.5% in pre-market trading after selling part of its e-commerce business to Stord.
The sale of part of its e-commerce business is seen as a positive move, likely improving the company's financial position and focusing on core operations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100